1887

Chapter 10 : Severe Legionnaires’ Disease Successfully Treated with Levofloxacin and Azithromycin

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Severe Legionnaires’ Disease Successfully Treated with Levofloxacin and Azithromycin, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815660/9781555813901_Chap10-1.gif /docserver/preview/fulltext/10.1128/9781555815660/9781555813901_Chap10-2.gif

Abstract:

Fluoroquinolones are the most active drugs against in intracellular and animal models, achieving high intracellular levels and low MICs. In patients with human immunodeficiency virus infection, Legionnaires' disease (LD) has a more severe clinical presentation and worse evolution, with a mortality rate of up to 20%. This chapter presents a case of a severely inmunosuppressed woman with LD in whom treatment failed with levofloxacin and who recovered after the addition of azithromycin. The intracellular location of the pathogen is relevant to the efficacy of the antibiotic. At present, new macrolides such as clarithromycin and azithromycin and fluoroquinolones are the most active drugs in the treatment of pneumonia. Even though the advances in rapid specific diagnosis and the greater efficacy of the new macrolides and quinolones have led to a better prognosis of pneumonia, mortality continues to be very high in immunosuppressed patients. Thus, randomized trials comparing the efficacy of combination therapies with new macrolides and quinolones versus monotherapy should be performed to evaluate their real impact in reducing morbidity and mortality of pneumonia with bad prognostic factors.

Citation: Pedro-Botet M, Sopena N, Tural C, García-Cruz A, Mateu L, Ragull S, García-Núñez M, Roure S, Rey-Joly C, Sabrià M. 2006. Severe Legionnaires’ Disease Successfully Treated with Levofloxacin and Azithromycin, p 40-42. In Cianciotto N, Kwaik Y, Edelstein P, Fields B, Geary D, Harrison T, Joseph C, Ratcliff R, Stout J, Swanson M (ed), . ASM Press, Washington, DC. doi: 10.1128/9781555815660.ch10

Key Concept Ranking

Highly Active Antiretroviral Therapy
0.53392625
0.53392625
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555815660.ch10
1. Blazquez-Garrido, R. M.,, F. J. Espinosa Parra,, L. Alemany Francés,, R. M. Ramos Guevara,, J. M. Sánchez-Nieto,, M. Segovia Hernández,, J. A. Serrano Martínez, and, F. Herrero Huerta. 2005.Antimicrobial chemotherapy for Legionnaires’ disease: levofloxacin versus macrolides. Clin. Infect. Dis. 40:800806.
2. Edelstein, P. H. and, M. A. C. Edelstein. 1991. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob. Agents Chemother. 35:180181.
3. Ishii, Y.,, M. Bando,, S. Ohno, and, Y. Sugiyama. 2005.A travel abroad-associated case of Legionella pneumonia diagnosed by urinary antigen detection test. Kansenshogaku Zasshi 79:290293.
4. Mykietiuk, A.,, J. Carratalà,, N. Fernández-Sabé,, J. Dorca,, R. Verdaguer,, F. Manresa, and, F. Gudiol. 2005. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin. Infect. Dis. 40:794799.
5. Oguma, A.,, T. Kojima,, D. Himeji,, Y. Arinobu,, I. Kikuchi, and, A. Ueda. 2004. A case of Legionella pneumonia complicated with acute respiratory distress syndrome treated with methylprednisolone and silvelestat sodium in combination with intravenous erythromycin and ciprofloxacin. Nihon Kokyuki Gakkai Zasshi 42:956960.
6. Okano, Y.,, T. Motoki,, M. Miki,, N. Hatakeyama, Y. Iwahara, Y. Nakamura, and, F. Ogushi. 2001.A case of Legionella pneumonia successfully treated intravenously with both erythromycin and ciprofloxacin.Nihon Kokyuki Gakkai Zasshi 39:949954.
7. Pedro-Botet, M. L.,, M. Sabrià,, N. Sopena,, M. García-Núñez, M.J. Domínguez,, E. Rey-naga, and, C. Rey-Joly. 2003. Legionnaires’ disease and HIV infection. Chest 124:543547.
8. Sabrià, M.,, M. L. Pedro-Botet,, J. Gómez,, J. Roig,, B. Vilaseca,, N. Sopena, and, V. Baños, for the Legionnaires’ Disease Therapy Group.2005. Fluoroquinolones versus macrolides in the treatment of Legionnaires’ disease. Chest 128:14011405.
9. Sabrià, M., and, V. L. Yu. 2002. Legionella species (Legionnaires’ disease), p. 395–417. In V. L. Yu, R. Weber, and D. Raoult, (ed.), Antimicrobial Therapy and Vaccines, 2nd ed. Apple Trees Productions, LLC, New York, N.Y.
10. Stout, J. E.,, K. Sens,, S. Mietzner, A. Obman, and, V. L. Yu. 2005. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intra-cellular susceptibility testing. Int. J. Antimicrob. Agents 25:302307
11. Stroup, J. S.,, S. E. Hendrickson, and, M. Neil. 2004. Legionella pneumonia and HIV infection: a case report. AIDSRead 14:267271.
12. Trubel, H. K.,, H. G. Meyer,, B. Jahn,, M. Knuf, W. Kamin, and, R. G. Huth. 2002. Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child. Scand. J. Infect. Dis. 34:219221.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error